![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
PUBLIC RELEASE DATE: 31-Oct-2013
[
]
ShareContact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Comparison of 2 third-generation drug-eluting stents establishes comparable safety and efficacy; demonstrates non-inferiorityof newest zotarolimus-eluting stent
SAN FRANCISCO, CA October 31, 2013 Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish the non-inferiority of the newest zotarolimus-eluting stent. The findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Third-generation permanent polymer-based drug-eluting stents (DES) with novel flexible designs were developed to improve stent deliverability in challenging anatomical lesions and to improve stent alignment within the vessel wall, while maintaining the anti-restenotic potential of newer generation DES systems. DUTCH PEERS (TWENTE II) follows the TWENTE trial, which was presented at TCT 2011 and examined second-generation drug-eluting stents with the same drugs and coatings but different stent platforms.
DUTCH PEERS was a multicenter, prospective, single-blinded, randomized controlled study in patients requiring percutaneous coronary interventions (PCI) with DES implantation. The study was performed in four PCI centers in the Netherlands (Thoraxcentrum Twente, Enschede; Rijnstate Hospital, Arnhem; Scheper Hospital, Emmen; Medical Center Alkmaar, Alkmaar). The primary endpoint was the composite target vessel failure (TVF) at one-year, defined as cardiac death, target vessel revascularization, or myocardial infarction (MI) attributable to the target vessel or not attributable to another vessel.
A total of 1,811 patients were randomly assigned to treatment with third-generation cobalt-chromium zotarolimus-eluting stents (906 patients; 1,205 lesions) or platinum-chromium everolimus-eluting stents (905 patients; 1,166 lesions). The study population (age 63.910.8 years, range 21 years; 73.0 percent male) was an "all-comers" population comprising 58.6 percent of patients with acute coronary syndromes (20.4 percent of all patients presented with an acute ST-elevation myocardial infarction). Of all 2,371 lesions, 65.7 percent were ACC/AHA lesion type B2/C. Follow-up data for 99.9 percent of the randomized patients were obtained.
TVF occurred in 6.1 percent (55/905) patients assigned to zotarolimus-eluting stents and 5.2 percent (47/905) assigned to everolimus-eluting stents. Non-inferiority of the zotarolimus-eluting stent was confirmed with an absolute risk difference of 0.88 percent (non-inferiority p-value = 0.006). There was also no significant between-group difference in individual components of the primary endpoint and other secondary clinical endpoints.
In both stent groups, definite-or-probable stent thrombosis rates were low. Definite-or-probable stent thrombosis rates were 0.6 percent (5/905) in the zotarolimus stent and 0.9 percent (8/905) in the everolimus stent (p value=0.40). Notably, there was no definite stent thrombosis beyond three months from stenting, reaffirming the safety of newer generation DES platforms.
"The clinical outcome of this trial was excellent particularly when considering its high proportion of complex patients with acute myocardial infarction at presentation and may represent a challenging touchstone of novel stents and scaffolds," said Clemens von Birgelen, MD PhD, the principal investigator of the trial. Dr. von Birgelen is Co-Director of the Department of Cardiology at Thoraxcentrum Twente and Professor of Cardiology at University of Twente in the Netherlands.
"Both permanent polymer-based stents were similarly efficacious and safe in treating all-comers with an excellent clinical outcome."
###
The DUTCH PEERS (TWENTE II) trial was equally funded by Boston Scientific and Medtronic. Dr. von Birgelen reported being a consultant to Abbott Vascular, Boston Scientific, and Medtronic. He has also received a travel grant from Biotronik and lecture fees from Biotronik and MSD.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.
[
Share]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
PUBLIC RELEASE DATE: 31-Oct-2013
[
]
ShareContact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Comparison of 2 third-generation drug-eluting stents establishes comparable safety and efficacy; demonstrates non-inferiorityof newest zotarolimus-eluting stent
SAN FRANCISCO, CA October 31, 2013 Results of the DUTCH PEERS (TWENTE II) clinical trial demonstrate comparable safety and efficacy of two third-generation permanent polymer-based drug-eluting stents with low rates of adverse clinical events and establish the non-inferiority of the newest zotarolimus-eluting stent. The findings were presented today at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Third-generation permanent polymer-based drug-eluting stents (DES) with novel flexible designs were developed to improve stent deliverability in challenging anatomical lesions and to improve stent alignment within the vessel wall, while maintaining the anti-restenotic potential of newer generation DES systems. DUTCH PEERS (TWENTE II) follows the TWENTE trial, which was presented at TCT 2011 and examined second-generation drug-eluting stents with the same drugs and coatings but different stent platforms.
DUTCH PEERS was a multicenter, prospective, single-blinded, randomized controlled study in patients requiring percutaneous coronary interventions (PCI) with DES implantation. The study was performed in four PCI centers in the Netherlands (Thoraxcentrum Twente, Enschede; Rijnstate Hospital, Arnhem; Scheper Hospital, Emmen; Medical Center Alkmaar, Alkmaar). The primary endpoint was the composite target vessel failure (TVF) at one-year, defined as cardiac death, target vessel revascularization, or myocardial infarction (MI) attributable to the target vessel or not attributable to another vessel.
A total of 1,811 patients were randomly assigned to treatment with third-generation cobalt-chromium zotarolimus-eluting stents (906 patients; 1,205 lesions) or platinum-chromium everolimus-eluting stents (905 patients; 1,166 lesions). The study population (age 63.910.8 years, range 21 years; 73.0 percent male) was an "all-comers" population comprising 58.6 percent of patients with acute coronary syndromes (20.4 percent of all patients presented with an acute ST-elevation myocardial infarction). Of all 2,371 lesions, 65.7 percent were ACC/AHA lesion type B2/C. Follow-up data for 99.9 percent of the randomized patients were obtained.
TVF occurred in 6.1 percent (55/905) patients assigned to zotarolimus-eluting stents and 5.2 percent (47/905) assigned to everolimus-eluting stents. Non-inferiority of the zotarolimus-eluting stent was confirmed with an absolute risk difference of 0.88 percent (non-inferiority p-value = 0.006). There was also no significant between-group difference in individual components of the primary endpoint and other secondary clinical endpoints.
In both stent groups, definite-or-probable stent thrombosis rates were low. Definite-or-probable stent thrombosis rates were 0.6 percent (5/905) in the zotarolimus stent and 0.9 percent (8/905) in the everolimus stent (p value=0.40). Notably, there was no definite stent thrombosis beyond three months from stenting, reaffirming the safety of newer generation DES platforms.
"The clinical outcome of this trial was excellent particularly when considering its high proportion of complex patients with acute myocardial infarction at presentation and may represent a challenging touchstone of novel stents and scaffolds," said Clemens von Birgelen, MD PhD, the principal investigator of the trial. Dr. von Birgelen is Co-Director of the Department of Cardiology at Thoraxcentrum Twente and Professor of Cardiology at University of Twente in the Netherlands.
"Both permanent polymer-based stents were similarly efficacious and safe in treating all-comers with an excellent clinical outcome."
###
The DUTCH PEERS (TWENTE II) trial was equally funded by Boston Scientific and Medtronic. Dr. von Birgelen reported being a consultant to Abbott Vascular, Boston Scientific, and Medtronic. He has also received a travel grant from Biotronik and lecture fees from Biotronik and MSD.
About CRF and TCT
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine. CRF is the sponsor of the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Celebrating its 25th anniversary this year, TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine. For more information, visit http://www.crf.org and http://www.tctconference.com.
[
Share]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2013-10/crf-ro103113.php
Related Topics: russell brand Nevada school shooting drew brees Bobby Cannavale kim zolciak
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.